Molecular coronary plaque imaging using 18F-fluoride by Moss, Alastair et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular coronary plaque imaging using 18F-fluoride
Citation for published version:
Moss, A, Doris, M, Andrews, J, Bing, R, Daghem, M, van Beek, E, Forsyth, L, Shah, A, Williams, M, Sellers,
SL, Leipsic, J, Parker, R, Newby, D & Adamson, P 2019, 'Molecular coronary plaque imaging using 18F-
fluoride', Circulation: Cardiovascular Imaging. https://doi.org/10.1161/CIRCIMAGING.118.008574
Digital Object Identifier (DOI):
10.1161/CIRCIMAGING.118.008574
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Circulation: Cardiovascular Imaging
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 12. Sep. 2019
Circ Cardiovasc Imaging. 2019;12:e008574. DOI: 10.1161/CIRCIMAGING.118.008574 August 2019 1
Alastair J. Moss, MD
Mhairi K. Doris, MD
Jack P.M. Andrews, MD
Rong Bing, MD
Marwa Daghem, MD
Edwin J. R. van Beek, MD, 
PhD
Laura Forsyth, PhD
Anoop S.V. Shah, MD, PhD
Michelle C. Williams, MD, 
PhD
Stephanie Sellers, PhD
Jonathon Leipsic, MD
Marc R. Dweck, MD, PhD
Richard A. Parker, BSc
David E. Newby, MD, PhD
Philip D. Adamson, MD, 
PhD
See Editorial by Salarian and Sadeghi
BACKGROUND: Coronary 18F-fluoride positron emission tomography 
identifies ruptured and high-risk atherosclerotic plaque. The optimal 
method to identify, to quantify, and to categorize increased coronary 
18F-fluoride uptake and determine its reproducibility has yet to 
be established. This study aimed to optimize the identification, 
quantification, categorization, and scan-rescan reproducibility of increased 
18F-fluoride activity in coronary atherosclerotic plaque.
METHODS: In a prospective observational study, patients with multi-
vessel coronary artery disease underwent serial 18F-fluoride positron 
emission tomography. Coronary 18F-fluoride activity was visually 
assessed, quantified, and categorized with reference to maximal tissue to 
background ratios. Levels of agreement for both visual and quantitative 
methods were determined between scans and observers.
RESULTS: Thirty patients (90% male, 20 patients with stable coronary 
artery disease, and 10 with recent type 1 myocardial infarction) 
underwent paired serial positron emission tomography-coronary 
computed tomography angiography imaging within an interval of 12±5 
days. A mean of 3.7±1.8 18F-fluoride positive plaques per patient was 
identified after recent acute coronary syndrome, compared with 2.4±2.3 
positive plaques per patient in stable coronary artery disease. The bias 
in agreement in maximum tissue to background ratio measurements in 
visually positive plaques was low between observers (mean difference, 
−0.01; 95% limits of agreement, −0.32 to 0.30) or between scans 
(mean difference, 0.06; 95% limits of agreement, −0.49 to 0.61). Good 
agreement in the categorization of focal 18F-fluoride uptake was achieved 
using visual assessment alone (κ=0.66) and further improved at higher 
maximum tissue to background ratio values.
CONCLUSIONS: Coronary 18F-fluoride activity is a precise and reproducible 
metric in the coronary vasculature. The analytical performance of 
18F-fluoride is sufficient to assess the prognostic utility of this radiotracer as 
a noninvasive imaging biomarker of plaque vulnerability.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. 
Unique identifiers: NCT02110303 and NCT02278211.
© 2019 The Authors. Circulation: 
Cardiovascular Imaging is published 
on behalf of the American Heart 
Association, Inc., by Wolters Kluwer 
Health, Inc. This is an open access 
article under the terms of the Creative 
Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
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Atherosclerotic plaque rupture is the commonest cause of acute coronary syndromes.1 Cardiovas-cular imaging modalities have focused on iden-
tifying the presence and severity of luminal stenoses 
to stratify the risk of plaque rupture events. However, 
luminal stenosis is a relatively late feature of coronary 
atherosclerosis, and the majority of rupture events oc-
cur at sites of nonobstructive plaque on antecedent 
angiography.2–4 As such, interest has grown in identify-
ing adverse atherosclerotic plaque characteristics and 
regions of increased disease activity within the arterial 
wall that may better predict subsequent plaque rup-
ture and clinical events. One promising approach has 
been to use combined positron emission tomography 
(PET) and computed tomography (CT) angiography that 
coregisters the detailed anatomy of the arterial wall 
with the in vivo biological activity of disease.5
To date, PET-CT has predominantly been used to 
evaluate the presence of inflammatory processes in 
large caliber arteries using the radiotracer 18F-fluorode-
oxyglucose.6 However, the application of this tracer to 
the coronary circulation is limited because background 
myocardial 18F-fluorodeoxyglucose uptake obscures and 
prevents assessment of coronary plaque activity.7 Recent 
studies have found that 18F-sodium fluoride (18F-fluo-
ride) holds major promise in identifying culprit plaques 
in the coronary circulation after myocardial infarction.5,7 
Validation work in the carotid arteries indicates that 
18F-fluoride also identifies culprit plaques after neuro-
vascular events and preferentially binds to microcalci-
fication, a key component of high-risk atherosclerotic 
plaque.8,9 Studies are now ongoing to assess the pro-
spective prognostic capability of coronary 18F-fluoride 
PET and whether the signal can help guide the use of 
novel therapies. However, coronary 18F-fluoride imaging 
is challenging due to the small caliber of the vessels and 
their near-continuous motion throughout the cardiac 
cycle.10,11 Moreover, there is a lack of consensus about 
image analysis techniques with a number of different 
approaches having been used. Hence, there is a need 
to optimize and to standardize coronary PET imaging 
methodology to facilitate the widespread application of 
coronary molecular imaging.
To address these issues, we undertook a prospective 
observational clinical study in patients with stable and 
unstable coronary artery disease that aimed to establish 
a reproducible methodology for identifying, quantify-
ing, and characterizing 18F-fluoride activity in the coro-
nary arteries.
METHODS
The data supporting the findings of this study are available 
from the corresponding author on reasonable request, within 
the limits of the ethical permits of the study.
Study Population
Participants were recruited within prespecified reproducibil-
ity substudies of the ongoing DIAMOND (Dual antiplatelet 
therapy to Inhibit coronary Atherosclerosis and Myocardial 
injury in patients with Necrotic high-risk coronary plaque 
Disease) and PRE18FFIR (Prediction of Recurrent Events with 
18F-Fluoride to Identify Ruptured and High-risk Coronary 
Artery Plaques in Patients with Myocardial Infarction) trials. 
Inclusion required the presence of multi-vessel coronary artery 
disease on invasive angiography, either after recent myocar-
dial infarction (PRE18FFIR), or in the context of stable coronary 
artery disease (DIAMOND). Exclusion criteria included inabil-
ity to receive iodinated contrast, renal impairment (estimated 
glomerular filtration rate ≤30 mL/min per 1.73 m2) or women 
of child-bearing potential. The study was approved by the 
local institutional review board, the Scottish Research Ethics 
Committee (REC reference: 14/SS/0089 and 15/SS/0203), and 
the United Kingdom Administration of Radiation Substances 
Advisory Committee. It was performed in accordance with the 
Declaration of Helsinki. All patients provided written informed 
consent before any study procedures.
18F-Fluoride PET and Coronary CT 
Angiography
All patients underwent 18F-fluoride PET-CT and coronary CT 
angiography scanning on 2 occasions 2 weeks apart using the 
same protocol. Patients were administered 50 to 100 mg oral 
metoprolol if their resting heart rate was >65 bpm before the 
intravenous administration of 250 MBq 18F-fluoride. After 60 
minutes, patients were imaged with a hybrid PET-CT scanner 
(64-multidetector Biograph mCT, Siemens Medical Systems, 
Erlangen, Germany). Attenuation correction CT scans were 
performed in held expiration before the acquisition of elec-
trocardiographic-gated list-mode PET data using a single 
30-minute bed position centered on the heart. Finally, an 
electrocardiographic-gated coronary CT angiogram (CCTA) 
CLINICAL PERSPECTIVE
Microcalcification is a key feature of coronary ath-
erosclerosis which may precipitate plaque rupture 
and thrombotic occlusion. 18F-Fluoride positron 
emission tomography is a novel imaging technique 
that readily identifies regions of coronary microcal-
cification. The objective of this article was to assess 
the repeatability of in vivo coronary 18F-fluoride 
positron emission tomography imaging to detect 
and quantify regions of microcalcification. Using 
a standardized metric (coronary to atrial blood 
pool ratio, maximum tissue to background ratio), 
18F-fluoride activity can be precisely and reproduc-
ibly measured within the coronary vasculature. The 
analytical performance of coronary 18F-fluoride 
activity is sufficient to determine whether this 
radiotracer can be used as a noninvasive imaging 
marker of plaque vulnerability in clinical trials.
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was performed in mid-diastole during held expiration. All 
patients received sublingual glyceryl trinitrate before CCTA.
Image Analysis
Electrocardiographic-gated PET images were reconstructed 
in diastole (50%–75% of the R-R interval, 2 iterations, 21 
subsets Siemens Ultra-HD algorithm) and fused with contrast-
enhanced CCTA. Analysis of the CT images was performed 
using dedicated software (Vitrea Advanced, Toshiba Systems) 
with multi-planar reformatting for plaque analysis used as 
necessary. Coronary arteries with a diameter ≥2 mm were 
assessed according to the 18-segment Society of Cardiac CT 
model.12 Qualitative and semi-quantitative analysis of the PET 
images from all 60 scans were performed independently by 
trained observers using an OsiriX workstation (OsiriX version 
3.5.1 64-bit; OsiriX Imaging Software, Geneva, Switzerland).
Identification of Coronary 18F-Fluoride 
Uptake
Coregistration of PET and CCTA images was undertaken to 
aid image interpretation in a 2 stage process. First, 18F-fluoride 
blood pool activity on the PET scan was aligned with contrast-
enhanced CCTA images of the cardiac chambers in 3 dimen-
sions using axial, sagittal, and coronal views of the heart. This 
approach is made possible by the increased blood pool activ-
ity of 18F-fluoride in comparison to the myocardium, allow-
ing the contours of the cardiac chambers to be determined 
on the PET images. Second, axial, coronal, and sagittal views 
were again interrogated in 3 dimensions to ensure optimal 
alignment of any tracer uptake in the aortic valve, aortic root, 
and the inner curve of the ascending aorta with the contrast 
CCTA (Figure I in the Data Supplement).
Visual assessment for increased coronary 18F-fluoride 
activity was performed on both a per-patient–level and per-
segment basis. For a signal to be colocalized to the coronary 
artery, a coronary atherosclerotic plaque had to be present 
on the CCTA, and the increased pattern of radiotracer had 
to arise from the coronary artery and follow its course over 
>5 mm in 3 dimensions on orthogonal views. Care was taken 
to exclude 18F-fluoride activity arising from adjacent struc-
tures, such as the aortic valve, mitral valve annulus, left atrial 
appendage, and the pulmonary artery.
Quantification of Coronary 18F-Fluoride 
Uptake
Semi-quantitative PET analysis was undertaken for all proxi-
mal coronary segments in addition to any atherosclerotic seg-
ment with focal 18F-fluoride activity as described above. First, 
maximum standardized uptake values (SUVMAX) were mea-
sured within regions of interest drawn around these areas. 
Due to the difficulties of drawing reproducible regions of 
interest around the perimeter of coronary segments, mean 
SUV values were not recorded.
SUVMAX values were corrected for background activity 
using several different methods. First, correction was made 
for uptake in a referent proximal coronary plaque with no 
evidence of increased 18F-fluoride activity.5,7 Second, correc-
tion was made for blood pool activity using elliptical regions 
of interest drawn within the brachiocephalic vein, superior 
vena cava, and all 4 cardiac chambers with mean standard-
ized uptake values (SUVMEAN) recorded for each region. To cal-
culate coronary target-to-background ratios (TBR), coronary 
SUVMAX was divided by these background measures providing 
TBRREFERENT and TBRMAX values, respectively.
Categorization of Coronary 18F-Fluoride 
Uptake
We next evaluated whether tracer quantification could be 
used to improve on the visual criteria described above for 
assessing coronary 18F-fluoride activity. 18F-Fluoride activity 
in plaques meeting visual criteria for positivity was quan-
tified and use to categorize plaques into the following 
groups: uptake below (TBR <0.9), similar to (TBR 0.9–1.1), 
and above (TBR >1.1) blood pool activity. This categorization 
was then applied to both patients with recent acute coro-
nary syndromes and stable coronary artery disease to assess 
the frequency of 18F-fluoride active lesions with the different 
thresholds. Discrepancies in reporting were resolved by con-
sensus adjudication (2 out of 3 blinded observers) of the pres-
ence of focal coronary 18F-fluoride activity.
Reproducibility of Coronary 18F-Fluoride 
Uptake
Repeat anonymized scans for all 30 patients were presented 
to 3 experienced observers in random order. Each observer 
performed scan analysis independent of the other readers. 
First, they determined the presence of coronary plaques with 
increased visual activity using the criteria for visual identifi-
cation described above. Second, they quantified activity in 
the coronary plaques which were referenced to background 
activity in the referent plaque, right atrium, left atrium, right 
ventricle, left ventricle, superior vena cava, and brachioce-
phalic vein. Coefficients of variation for each of these back-
ground measurements were then calculated. Subsequently, 
coefficients of variation were calculated for each metric of 
coronary 18F-fluoride activity (eg, SUVMAX, TBRMAX, TBRREFERRENT, 
etc). Finally, we assessed the agreement of these metrics 
across serial scans using visual categorization in isolation, and 
in combination with a low semi-quantitative threshold (TBR 
>0.9) or a high semi-quantitative threshold (TBR >1.1).
Statistical Analysis
Continuous variables are reported as mean±SDor median 
and interquartile range. Categorical variables are reported as 
absolute number and percentages. Paired t tests were used 
to determine statistical significance for comparisons of means 
with normal distribution. Consensus observer agreement 
(2 out of 3 observers) of coronary segment tracer localiza-
tion was used to adjudicate positive focal tracer uptake, and 
the presence of a single positive segment was sufficient for 
a patient-level diagnosis of 18F-fluoride positivity. Limits of 
agreement analysis were conducted to assess scan-rescan and 
interobserver repeatability for all coronary segments and visu-
ally positive coronary plaques using TBRMAX adjusted for the 
left atrial blood pool. After the mixed-effects limits of agree-
ment methodology of Parker et al,13 a mixed-effects model 
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was fitted to the TBRMAX between-scan paired differences with 
segment included as a random effect nested within patient, 
adjusting for study (DIAMOND or PRE18FFIR), and observer 
as fixed effects. The mixed model for the TBRMAX between-
observer paired differences was similar but with scan number 
and observer comparison as fixed effects instead of observer. 
In both cases, the mean bias was separately estimated based 
on a model only including the nested random effects of seg-
ment within patient.13 Variance components concordance 
correlation coefficients (CCC) were computed as an addi-
tional measure of scan-rescan and inter-rater agreement using 
mixed-effects methodology suitable for repeated measures 
data.14 Specifically, we fitted a mixed-effects model to the raw 
outcome data including nested random effects of segment 
within patient and adjusting for observer, study (DIAMOND or 
PRE18FFIR), scan (first or second), and the global mean as fixed 
effects. For assessment of scan-rescan agreement we included 
the scan-rescan variance in the denominator of the repeated 
measures CCC formula, whereas for interobserver agreement 
we included the between-observer variance in the denomina-
tor instead. Note that the CCC is strongly dependent on the 
between-segment and between-patient variability. Pan et al15 
suggest that the CCC variance components method calcu-
lated using mixed-effects modeling could also be applied to 
binary outcome data, and concludes that the method works 
well when the proportions are not too extreme. Therefore, 
the same CCC method was used to measure agreement of 
the binary visual uptake outcome to produce a kappa-type 
statistic κ. The κ values were interpreted as follows: poor 
≤0.20, fair 0.21 to 0.4, moderate 0.41 to 0.60, good 0.61 
to 0.80, and very good ≥0.81. A nonparametric bootstrap 
method was used to compute 95% bias-corrected percentile 
CI for the CCC estimates. Statistical analysis was performed 
using R version 3.5.3 (R Foundation for Statistical Computing, 
Vienna, Austria). Statistical significance was taken as P<0.05.
RESULTS
Thirty patients (90% male, 20 patients with stable coro-
nary artery disease, and 10 with recent type 1 myocardi-
al infarction) underwent serial PET-CCTA imaging within 
12±5 days. Cardiovascular risk factors were common, 
and 28 (93.3%) patients had undergone prior coronary 
revascularisation (22 percutaneous coronary interven-
tion and 9 coronary artery bypass grafting; Table 1).
Blood Pool 18F-Fluoride Activity
18F-Fluoride blood pool activity was consistently higher in 
all 4 cardiac chambers than in the myocardium (blood 
pool SUVMEAN 1.14 versus interventricular septum SUVMEAN 
0.80; Figure  1, FigureII in the Data Supplement). This 
facilitated accurate manual coregistration of the PET and 
CCTA data sets as described above (Figure I in the Data 
Supplement). Background measurements in the referent 
plaque, brachiocephalic vein, and the superior vena cava 
were consistently lower than cardiac blood pool with 
high coefficients of variation. The regions with the least 
variability in serial measurements of background activity 
(SUV
MEAN) were the cardiac atria with coefficients of varia-
tion in the left and right atria of 5.9±2.8% and 6.5±2.5%, 
respectively (Figure 1, Table I in the Data Supplement).
Identification of Coronary 18F-Fluoride 
Uptake
Low myocardial 18F-fluoride uptake enabled visual sepa-
ration between areas of focal 18F-fluoride binding in the 
coronary arteries and background blood pool activity in 
the cardiac chambers. After accurate coregistration, these 
factors facilitated the identification of radiotracer origi-
nating from the coronary arteries even at levels of inten-
sity similar to background blood pool activity that would 
otherwise not be discernible (Figure 2). Using this meth-
od, focal coronary 18F-fluoride activity of variable intensity 
Table 1. Baseline Characteristics of Study Population
All 
Patients
Patients 
With 
Recent 
Myocardial 
Infarction
Patients 
With Stable 
Coronary 
Heart 
Disease
N 30 10 20
Age, y 67.3±7.6 62.83±6.30 69.53±7.32
Male 27 (90) 10 (100) 17 (85)
Body mass index, kg/m2 28.3±4.2 29.8±4.40 27.51±3.97
Medical history
  Previous myocardial infarction 23 (77) 10 (100) 13 (65)
  Coronary revascularization 28 (93.3) 9 (90) 16 (80)
   Percutaneous coronary 
intervention
22 (63) 9 (90) 13 (50)
   Coronary artery bypass 
grafting
9 (20) 0 9 (30)
  Hypertension 17 (57) 3 (30) 14 (70.0)
  High cholesterol 26 (87) 6 (60) 20 (100)
  Diabetes mellitus 5 (17) 3 (30) 2 (10)
  Prior stroke/transient 
ischemic attack
1 (3) 0 1 (5)
  Atrial fibrillation 1 (3) 0 1 (5)
  Peripheral vascular disease 1 (3) 0 1 (5)
Medications
  Aspirin 30 (100) 10 (100) 20 (100)
  P2Y12 antagonist 10 (33) 10 (100) 0
  Statin 30 (100) 10 (100) 20 (100)
  β-blocker 13 (43) 4 (40) 9 (45)
  Angiotensin-converting 
enzyme inhibitor/angiotensin 
II receptor blocker
25 (83) 8 (80) 17 (85)
Creatinine, mg/dL 0.9±0.2 1.0±0.2 0.9±0.1
Estimated glomerular filtration 
rate, mL/min per 1.73m2
98.5±16.9 94.6±17.6 100.4±16.7
Interscan interval, days 12.3±5.1 13.9±6.1 11.5±4.5
Values are n (%) or mean±SD.
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could be visually identified in all culprit plaques (n=10) in 
patients with recent type 1 myocardial infarction.
Quantification of Coronary 18F-Fluoride 
Uptake
Quantification of coronary 18F-fluoride activity within the 
plaque of interest, standardized according to a proximal 
nondiseased coronary artery segment (TBRREFERENT) demon-
strated a high degree of variability on repeated measure-
ments. The coefficients of variation reduced in a stepwise 
manner when using the brachiocephalic vein and supe-
rior vena cava as the sites of measurement for blood pool 
activity and were lowest for target-to-background ratios 
determined after standardization for intracardiac blood 
pool activity using either the left or right atria (P<0.05 for 
all comparisons, Figure III in the Data Supplement). There-
fore, subsequent analyses used TBRMAX values standard-
ized according to the atrial blood pool, with 18F-fluoride 
originating in the coronary arteries categorized into lev-
els below (TBRMAX <0.9), similar to (TBRMAX 0.9–1.1) and 
above (TBRMAX >1.1) atrial blood pool activity (Figure 3).
Categorization of Coronary 18F-Fluoride 
Uptake
Using atrial blood pool as a point of reference allowed 
comparison of coronary 18F-fluoride TBRMAX between 
patients with recent acute coronary syndromes and stable 
coronary artery disease. At the patient level, there were 
3.7±1.8 positive plaques in patients with recent acute 
coronary syndrome compared with 2.4±2.3 positive 
plaques in patients with stable disease. Among patients 
with recent myocardial infarction, 100% (n=10/10) of 
culprit plaque segments met the criteria for visual uptake 
compared with 13.7% (n=73/530) of all segments not 
associated with plaque rupture. Visual assessment of 
coronary segment positivity achieved good interobserver 
reliability (κ=0.66, 95% CI, 0.63–0.70). Minor discrepan-
cies between reporters occurred in regions adjacent to 
high background activity including the right atrial blood 
pool, pulmonary artery and mitral valve annulus that 
limited assessment in regions of the right, left anterior 
descending artery, and atrioventricular circumflex arter-
ies, respectively. Agreement increased among coronary 
segments with higher TBRMAX values and the application 
of a semi-quantitative method of determining 18F-fluoride 
positivity, requiring both visual evidence of tracer localiza-
tion to a coronary region of interest and TBRMAX above 
the prespecified intensity thresholds achieved good scan-
rescan agreement at both predefined cut points (TBRMAX 
>0.9, κ=0.72; 95% CI, 0.67–0.77; TBRMAX >1.1 κ=0.77; 
95% CI, 0.71–0.83; Figure 3 and Figure IV in the Data 
Supplement). When applied to patients with recent myo-
cardial infarction, the use of TBRMAX thresholds resulted 
in fewer culprit plaques being classified as positive for 
focal 18F-fluoride uptake (n=7/10 [70%] at TBRMAX ≥0.9; 
n=2/10 [20%] at TBRMAX >1.1).
Reproducibility of Coronary 18F-Fluoride 
Uptake
There were no differences in scan variables between the 
serial scans (Table II in the Data Supplement). Patients 
Figure 1. Background blood pool and cardiac 18F-fluoride activity.  
The mean standardized uptake value (SUVMEAN; g/mL) in each region was compared by 3 observers across 2 scans. A, Box-plot of the median and the interquar-
tile range of coefficients of variation for each region (black line, mean). There was no difference in the coefficients of variation of 18F-fluoride SUVMEAN within 
intracardiac chambers (red), but there were increased coefficients of variation using systemic venous blood pool measurement (P<0.001) and interventricular septal 
myocardium (P<0.001) compared with measurement of SUVMEAN 
18F-fluoride activity in the left atrium. B, Box-plot of the median and the interquartile range of 
mean standardized uptake values for brachiocephalic, superior vena cava, right atrium, and interventricular septum (black line, mean). Note the low myocardial 
and background coronary arterial 18F-fluoride uptake compared with blood pool in the right atrium. BCV indicates brachiocephalic vein; IVS, interventricular 
septum; LA, left atrium; LV, left ventricle; NS, not-significant; RA, right atrium; RV, right ventricle; and SVC, superior vena cava. *P≤0.05; †P≤0.01; ‡P≤0.001; and 
§P≤0.0001.
D
ow
nloaded from
 http://ahajournals.org by on August 23, 2019
Circ Cardiovasc Imaging. 2019;12:e008574. DOI: 10.1161/CIRCIMAGING.118.008574 August 2019 6
Moss et al; Coronary 18F-Fluoride Reproducibility
with stable coronary artery disease had an increased 
dose-length product than patients with recent MI due 
to the wider field of view on coronary CT angiogra-
phy required for assessing the origin of the left internal 
mammary artery in cases of previous coronary artery 
bypass grafting. In all measured coronary segments 
(n=519), there was a mean bias of −0.03 between 
observers (95% limits of agreement −0.39 to 0.33) 
and a mean bias of 0.04 between scans (95% limits 
of agreement −0.41 to 0.49; Table 2 and Figure 4). In 
visually positive plaques, mixed-effects biases were low 
between observers (mean bias −0.01; 95% limits of 
agreement −0.32 to 0.30) and between scans (mean 
bias 0.06, 95% limits of agreement −0.49 to 0.61; 
Table  2). There was very good concordance between 
observers (concordance correlation coefficient 0.88; 
95% CI, 0.85 to 0.90) and between scans (concordance 
correlation coefficient 0.86; 95% CI, 0.83 to 0.89). At 
the level of the patient, there was 100% agreement 
between the repeat scans on whether a patient dem-
onstrated any increased coronary 18F-fluoride activity 
in at least one plaque. At the per-segment level, there 
was excellent agreement (92.4%) between scans using 
the visual assessment alone, although further improve-
ments in agreement were achieved by applying the 
TBRMAX thresholds (93.0% agreement rate TBRMAX ≥0.9; 
94.2% agreement rate TBRMAX >1.1; Figure IV in the 
Data Supplement).
DISCUSSION
This study describes an optimized methodology for 
assessing coronary 18F-fluoride activity in vivo. Using 
this approach, there is good agreement in the identi-
fication of plaques with increased coronary 18F-fluoride 
uptake between observers and on different scans. 
The tissue (SUVMAX) to background (left atrial SUVMEAN) 
ratio (TBRMAX) has a low bias between observers and 
Figure 2. Culprit plaque 18F-fluoride activity on positron emission tomography-coronary computed tomography angiography (PET-CT).  
After acute myocardial infarction, culprit plaque 18F-fluoride activity can be measured in the right coronary artery (A–F), left anterior descending artery (G–I), and 
atrioventricular circumflex artery (J–L).
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between scans. At TBRMAX thresholds >0.9, there is low 
sampling variability and high interobserver agreement 
in the adjudication of coronary 18F-fluoride activity. 
18F-Fluoride demonstrates optimal characteristics for 
coronary plaque molecular imaging, namely, low myo-
cardial and background coronary artery activity which 
allows regions of increased coronary 18F-fluoride uptake 
to be more readily detected at low levels of intensity. 
Figure 3. Quantification of coronary 18F-fluoride activity.  
Visual identification of coronary 18F-fluoride activity was present in all ruptured plaques and 13.8% of stable coronary segments. The signal intensity of 18F-fluoride 
activity in coronary plaque was assessed both visually and semi-quantitatively by referencing to atrial blood pool activity (maximum target-to-background ratio 
[TBRMAX]). Activity in coronary plaques was categorized into activity above blood pool (TBRMAX >1.1), at or around blood pool (TBRMAX 0.9–1.1), or below blood pool 
(TBRMAX <0.9). Higher intensity signals were observed in stable segments compared with ruptured plaques.
D
ow
nloaded from
 http://ahajournals.org by on August 23, 2019
Circ Cardiovasc Imaging. 2019;12:e008574. DOI: 10.1161/CIRCIMAGING.118.008574 August 2019 8
Moss et al; Coronary 18F-Fluoride Reproducibility
This technique has direct application to ongoing clinical 
trials using the identification of atherosclerotic plaque 
mineralization to predict coronary events and improve 
the stratification of emerging therapeutic interventions.
Our study has a number of notable strengths. First, 
this is the largest prospective study to investigate the 
scan-rescan reproducibility of coronary imaging with 
repeated 18F-fluoride PET-CT scans. Second, the study 
population comprising 30 patients with established, 
multi-vessel coronary disease represents a high-risk 
cohort for whom imaging biomarkers have genuine 
potential to improve prognostic stratification and guide 
therapeutic interventions. Third, we directly compared 
several proposed methods for quantifying focal tracer 
activity within coronary atherosclerotic lesions and deter-
mined the interobserver and scan-rescan agreement for 
these metrics. Lastly, we derived a standardized semi-
quantitative approach to image analysis that allows con-
sistency in the reporting of diagnostic findings.
For an imaging biomarker to have clinical utility, it 
should demonstrate precise and reproducible analyti-
cal performance.16 Specifically, precision refers to the 
closeness of agreement between independent obser-
vations under stipulated conditions (free from random 
error) and reproducibility reflects to the differences 
observed over separate scan acquisitions. The meth-
odology of coronary 18F-fluoride assessment presented 
here has been optimized to define a precise measure 
of background activity (cardiac atria) that yields a pre-
cise measure of coronary activity (TBRMAX) across serial 
scan acquisitions. Demonstrating the reliability of this 
metric is an important step towards implementing 
coronary PET imaging in clinical practice and prospec-
tive research trials. We suggest such studies apply 
similar acquisition and image analysis protocols to that 
described here, and continue to explore the clinical sig-
nificance of such measurements.
To discriminate 18F-fluoride uptake from levels of 
background signal, focal coronary artery activity has 
previously been referenced to proximal nondiseased 
coronary artery segments (TBRREFERENT).
5,7 Although 
this practice differs from noncoronary 18F-fluoride PET 
imaging, it has been considered more appropriate to 
reference to a similar sized structure rather than a large 
blood pool region to avoid artificially low TBR values 
related to partial volume effects. However, we found 
this metric to have a high degree of variability on serial 
testing, due to inconsistency in measurements in the 
referent plaque. This likely reflects the inherent dif-
ficulty in reproducibly measuring a coronary segment 
without visual 18F-fluoride activity compared with the 
much easier agreement between observers when draw-
ing a region of interest around a focal site of tracer 
uptake. Of note, this study identified 18F-fluoride activ-
ity within distal and side branch vessels that may be 
more susceptible to partial volume averaging effects. 
In these regions, activity may spill out into surrounding 
structures, thereby decreasing counts in plaques which 
would otherwise have increased activity. Similarly, cor-
onary segments in close proximity to calcified tissue 
in the aortic and mitral annulus may be subjected to 
spill-in of 18F-fluoride activity in regions that would oth-
erwise have low activity. These small changes in localiza-
tion of maximal activity explain the variation observed 
when measuring structures below the field-width half 
maximum of 18F-fluoride (6 mm). Future work using 
an increased delay between injection and acquisition17 
optimizing the reconstruction algorithm and motion-
correcting the list mode data18 may improve quanti-
tative reproducibility. Thus, quantification of activity 
should only be undertaken in plaques that meet the 
visual criteria stipulated in the methodology.
Our optimized methodology for estimating back-
ground blood pool activity also differs from previous 
18F-fluorodeoxyglucose cardiovascular PET studies. Here, 
background blood pool activity is measured within the 
large venous capacitance vessels, such as the superior 
vena cava.19,20 This is preferred over measurements from 
within the cardiac chambers because 18F-fluorodeoxyglu-
cose is taken up by viable myocardium and blood pool 
activity can be contaminated by signal overspill from the 
myocardium. In contrast, there is very low myocardial 
uptake of 18F-fluoride and thus estimating atrial blood 
pool activity is not susceptible to this confounding issue. 
Table 2. Mixed-Effects Limits of Agreement Analysis Between Scans and Observers for All Segments and Visually Positive Plaques
All Segments Visually Positive Plaques
Between scan CCC CCC, 0.88; 95% CI, 0.87 to 0.90 CCC, 0.86; 95% CI, 0.83 to 0.89
Between observer CCC CCC, 0.89; 95% CI, 0.87 to 0.90 CCC, 0.88; 95% CI, 0.85 to 0.90
Between scan Kappa VU CCC, 0.69; 95% CI, 0.65 to 0.72  
Between observer Kappa VU CCC, 0.66; 95% CI, 0.63 to 0.70  
Between scan limits of agreement Mean bias 0.04, 95% limits of agreement are from −0.41 
to 0.50. between segment SD 0.12, between patient SD 
0.12, Residual SD 0.15
Mean bias 0.06, 95% limits of agreement are from −0.49 
to 0.61. Between segment SD 0.16, between patient SD 
0.18, residual SD 0.15
Between observer limits of 
agreement
Mean bias −0.027, 95% limits of agreement are from 
−0.386 to 0.332, between segment SD 0.065, between 
patient SD 0.030, residual SD 0.169
Mean bias −0.0068, 95% limits of agreement are from 
−0.316 to 0.303. Between segment SD 0.040, between 
patient SD 0.023, residual SD 0.151
CCC indicates concordance correlation coefficient; VU, variable unit.
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The superior vena cava can be a relatively small com-
pressed structure sensitive to sampling error and partial 
volume effects whereas the atria present larger spherical 
volumes of activity that can be more readily and reli-
ably sampled, providing a measurement with higher 
precision and reproducibility. Thus for tracers with a low 
background myocardial uptake, background blood pool 
activity would appear to be best measured in the car-
diac atria. Consequently, although standardization of 
coronary activity with reference to the atrial blood pool 
(TBRMAX) resulted in numerically lower values than when 
standardized according to either a referent coronary 
segment or an extracardiac blood pool, the coefficients 
of variation were much reduced. Indeed, because the 
referent plaque uptake is lower (0.7–0.8 of that in the 
atrial blood pool), our previous TBRMAX threshold of 1.25 
equates to a TBRMAX threshold 0.9 to 1.0 when using 
the atrial blood pool activity. This finding has impor-
tant implications for future studies that seek to mea-
sure change in tracer signal over serial scans, either to 
explore the natural history of plaque vulnerability or to 
use this metric as a surrogate for therapeutic response.
While quantitative measurements of 18F-fluoride 
activity have particular relevance to serial imaging 
studies, it is not clear that the numeric value of the 
TBRMAX has direct correlation with plaque vulnerabil-
ity. Indeed, we found that among patients with acute 
myocardial infarction, the culprit plaques demonstrated 
proportionally lower TBRMAX values than visually posi-
tive plaques in patients with clinically stable disease. 
Although somewhat counterintuitive, this finding is 
consistent with our previous report,7 and the relation-
ship between TBRMAX and risk of future clinical events 
remains to be determined in large-scale prospective 
trials, such as the PRE18FFIR trial. Indeed, it should be 
remembered that 18F-fluoride uptake correlates with 
microcalcification and is a marker of calcification activ-
ity.7 While it identifies high-risk plaque with a necrotic 
core, the magnitude of uptake may reflect different 
stages of the calcification process, and it may be the 
presence rather than the magnitude of uptake that is 
most important. For example, high 18F-fluoride uptake 
may represent advanced calcification activity with rap-
idly developing macrocalcification, which is stabilizing 
the plaque and making it less prone to rupture. Con-
versely, relatively lower levels of 18F-fluoride uptake may 
represent the immediate response to a recently devel-
oped unstable plaque with a necrotic core that has yet 
to develop demonstrable macrocalcification and has 
only nascent calcification activity.
We have demonstrated good reliability for visual 
assessment alone in the identification of culprit plaques 
after recent acute coronary syndrome. Perhaps unsur-
prisingly, the interobserver and scan-rescan agreement 
for the classification of 18F-fluoride positivity within a 
coronary segment increased inline with the TBRMAX 
and was greatest for coronary segments with maxi-
mum standardized uptake values >1.1×the blood pool 
Figure 4. Bland-Altman plots of coronary 18F-fluoride activity.  
Correlation and Bland-Altman plots for scan-rescan reproducibility for coronary plaques at different levels of coronary 18F-fluoride activity (TBRMAX; A and C, 
respectively). Correlation and Bland-Altman plots for interobserver reproducibility between 2 observers at different levels of 18F-fluoride activity (TBRMAX; B and D, 
respectively). The shaded circles represent individual observations whilst the red and grey hatched lines represent the mean difference and 95% mixed-effects limits 
of agreement, respectively.
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SUVMEAN. In this regard, a recent cohort study has dem-
onstrated that coronary TBRMAX ≥1.28 stratified indi-
viduals at increased risk of plaque rupture.21 While this 
higher patient-level threshold identified individuals at 
risk of late coronary revascularisation, at the plaque-
level 45% of culprit plaques (n=5/11) did not meet this 
threshold.21 This observation is inkeeping with our find-
ing that culprit plaque 18F-fluoride activity, while readily 
identifiable, is often at a lower intensity than blood pool 
which future studies may need to account for. The iden-
tification of low-intensity 18F-fluoride activity needs to 
be prospectively evaluated in future studies of repeated 
imaging following an acute coronary syndrome.
This study has a number of limitations. It was under-
taken in a single center with extensive experience in 
cardiac 18F-fluoride PET-CCTA imaging and scans were 
performed using a single PET-CCTA scanning system. It 
is important to acknowledge that many operator and 
system-dependent variables can influence final image 
quality, and these will necessitate careful consider-
ation when applying our findings in different settings. 
A number of limitations of our study are inherent to 
coronary PET imaging, and include the challenges of 
nonspecific binding, cardiac motion, partial voluming, 
and relatively low signal-to-noise ratios. We chose to 
use 18F-fluoride as our PET tracer as there is low physi-
ological activity within the myocardium, reducing the 
chance for spill-in activity. Furthermore, we have previ-
ously established that the problem of cardiac motion 
can be overcome through electrocardiographic-gating 
in a similar manner to that employed in coronary CT 
angiography.22 Although restricting the analysis of the 
PET signal to one-quarter of the cardiac cycle reduces 
the signal-to-noise ratio, we have now compensated 
for this by increasing tracer dose, increasing scan dura-
tion, and applying advanced image reconstruction 
algorithms including time-of-flight reconstruction with 
point spread function modeling. In combining these 
incremental gains, we have derived a semi-quantita-
tive measure of plaque pathophysiology that is highly 
reproducible on interval scanning and is well placed for 
observing dynamic changes in activity over time.
In conclusion, 18F-fluoride PET-CCTA imaging is high-
ly reproducible over repeated scans and between mul-
tiple observers. A semi-quantitative approach achieves 
repeatable metrics than can now be assessed to deter-
mine their clinical significance. This approach to image 
acquisition and analysis provides strong support for 
the ongoing clinical studies investigating the value of 
18F-fluoride PET-CCTA to inform cardiovascular prognos-
tic assessment and guide novel therapeutic strategies.
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